PROASSURANCE Business Summary

ProAssurance Corporation (PRA) is a specialty insurance holding company that generates revenue primarily through premiums and investment income across five business segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. Its core business focuses on medical professional liability (MPL) for healthcare providers, products liability for medical technology firms, and legal professional liability. The company maintains a significant market presence by providing risk management solutions to individual practitioners and large-scale healthcare systems. ProAssurance competes directly with major carriers such as Arch Capital Group, American Financial Group, and Chubb, as well as niche specialists like The Doctors Company. Positioned as a high-touch, expertise-driven insurer, ProAssurance is currently executing a $1.3 billion definitive merger agreement with The Doctors Company, expected to finalize in the first half of 2026, which will consolidate its market leadership and transition the company from a public entity to a private subsidiary. The leadership team is headed by President and CEO Edward "Ned" L. Rand Jr., a veteran executive who joined the company in 2004 and previously held the roles of CFO and COO after a career at PartnerRe and Atlantic American. He is supported by EVP and CFO Dana S. Hendricks, who has managed the company’s financial strategy since 2018, and Jeffrey P. Lisenby, who serves as General Counsel and Corporate Secretary. Founded in 1976 by a group of physicians to stabilize the medical malpractice market, the company’s board is currently chaired by Bruce D. Angiolillo, a retired partner of Simpson Thacher & Bartlett. Other prominent board members include Samuel A. Di Piazza Jr., former Global CEO of PricewaterhouseCoopers, and Richard J. Bielen, CEO of Protective Life Corporation. Major institutional shareholders include Vanguard, BlackRock, and Dimensional Fund Advisors, whose stakes are set to be cashed out upon the completion of the pending acquisition by The Doctors Company.